To amend title XVIII of the Social Security Act to extend eligibility for certain payment increases for biosimilar biological products under the Medicare program.

HR 6400 extends the deadline for Medicare to provide certain payment increases to biosimilar biological products from 2027 to 2032. This affects Medicare beneficiaries who use these lower-cost biosimilar drugs and the pharmaceutical companies that manufacture them. The bill makes a technical change to an existing provision in the Social Security Act, simply updating the expiration date without altering the underlying payment structure.